Log in

Relevant bibliographies by topics / Immunotherapy / Journal articles

To see the other types of publications on this topic, follow the link: Immunotherapy.

Journal articles on the topic 'Immunotherapy'

Author: Grafiati

Published: 4 June 2021

Last updated: 5 October 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Immunotherapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Bakulesh, Khamar. "Immunotherapy of Bladder Cancer." Cancer Medicine Journal 3, no. 2 (December 31, 2020): 49–62. http://dx.doi.org/10.46619/cmj.2020.3-1020.

Full text

Abstract:

Bladder cancer used to be the only cancer treated by immunotherapy in form of intravesical BCG. Since approval of BCG for Non muscle invasive bladder cancer (NMIBC), there has been significant advancement in our knowledge about immune alteration in cancer and availability of immunotherapeutic agents. Tumor induced cell mediated immunosuppression is identified as a key factor for development and progression of cancer. Immune suppression in bladder cancer is predominantly through Macrophages. Myeloid derived suppressor cell, NK cells, Treg and expression of immune checkpoint receptor inhibitors also contribute to immune suppression. BCG induces innate immune response and its efficacy is limited to NMIBC. Novel immunotherapeutic agents evaluated in bladder cancer are administered locally or systemically to induce innate or adaptive immune response. Systemic administration of antibodies against PD-1/PD-L1 axis are now approved for treatment of locally advanced/metastatic bladder cancer as a first line as well as second line therapy. Pembrolizumab is also approved for BCG unresponsive NMIBC. Since response to immunotherapy are neither uniform nor universal, attempts are made to identify prognostic and predictive biomarkers. Identified biomarkers lack desired specificity and sensitivity. Several immune approaches using innate as well as adaptive mechanism are under evaluation to improve outcome of intravesical BCG or immune check point receptor inhibitors.

APA, Harvard, Vancouver, ISO, and other styles

2

Kim, Edwin H., and Arvil Wesley Burks. "Food allergy immunotherapy: Oral immunotherapy and epicutaneous immunotherapy." Allergy 75, no. 6 (February 28, 2020): 1337–46. http://dx.doi.org/10.1111/all.14220.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Fay, Emily K., and Julie N. Graff. "Immunotherapy in Prostate Cancer." Cancers 12, no. 7 (July 1, 2020): 1752. http://dx.doi.org/10.3390/cancers12071752.

Full text

Abstract:

Immunotherapy encompasses a wide range of therapies to engage the immune system to target malignancies. In recent years, immunotherapy has made a major impact on treatment of metastatic cancer and has altered standard of care for many tumor types. However, predicting and understanding responses across tumor types has been challenging. While some metastatic cancers have shown dramatic responses to immunotherapy, such as melanoma, lung cancer, and renal cell carcinoma, prostate cancer has generally failed to show a significant response. However, small series of prostate cancer patients have shown impressive responses to cellular and immunotherapy. This review summarizes the current data for immunotherapy’s use in prostate cancer, as well as how currently available data might help predict patient responses to immunotherapy. Specifically, we will review vaccine-based therapies, immune checkpoint inhibitors, and future directions that are actively being explored.

APA, Harvard, Vancouver, ISO, and other styles

4

Bintintan, Vasile, Claudia Burz, Irena Pintea, Adriana Muntean, Diana Deleanu, Iulia Lupan, and Gabriel Samasca. "Predictive Factors of Immunotherapy in Gastric Cancer: A 2024 Update." Diagnostics 14, no. 12 (June 13, 2024): 1247. http://dx.doi.org/10.3390/diagnostics14121247.

Full text

Abstract:

Many studies on gastric cancer treatment have identified predictors of immunotherapy benefits. This article provides an update on the major developments in research related to predictive factors of immunotherapy for gastric cancer. We used the search term “predictive factors, immunotherapy, gastric cancer” to find the most current publications in the PubMed database related to predictive factors of immunotherapy in gastric cancer. Programmed cell death, genetic, and immunological factors are the main study topics of immunotherapy’s predictive factors in gastric cancer. Other preventive factors for immunotherapy in gastric cancer were also found, including clinical factors, tumor microenvironment factors, imaging factors, and extracellular factors. Since there is currently no effective treatment for gastric cancer, we strongly propose that these studies be prioritized.

APA, Harvard, Vancouver, ISO, and other styles

5

Nelson, Harold S., Melina Makatsori, and Moises A. Calderon. "Subcutaneous Immunotherapy and Sublingual Immunotherapy." Immunology and Allergy Clinics of North America 36, no. 1 (February 2016): 13–24. http://dx.doi.org/10.1016/j.iac.2015.08.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Sveikata, Lukas, Andreas Charidimou, and Anand Viswanathan. "Vessels Sing Their ARIAs: The Role of Vascular Amyloid in the Age of Aducanumab." Stroke 53, no. 1 (January 2022): 298–302. http://dx.doi.org/10.1161/strokeaha.121.036873.

Full text

Abstract:

We review the implications of the recently approved aducanumab amyloid-β immunotherapy for treating Alzheimer disease with comorbid cerebral amyloid angiopathy. In clinical trials, amyloid-β immunotherapy has been associated with a high rate of amyloid-related imaging abnormalities, potentially driven by coexisting cerebral amyloid angiopathy. Therefore, immunotherapy’s efficacy in patients may be modified by coexisting cerebrovascular pathology. We discuss the contributions of cerebral amyloid angiopathy on the development of amyloid-related imaging abnormalities and propose strategies to identify cerebral amyloid angiopathy in patients considered for immunotherapy.

APA, Harvard, Vancouver, ISO, and other styles

7

S V S, Gulakavarapu, Narapaneni Sravanthi, Praneeth Ulavala, and S. Chandrababu. "Immunotherapy and the Management of Allergies: An Overview of Monoclonal Antibody Therapy and Allergen Immunotherapy." International Journal of Science and Research (IJSR) 12, no. 9 (September 5, 2023): 1051–53. http://dx.doi.org/10.21275/mr23911124247.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Shi, Junhan. "Applications of immune checkpoint inhibitors (ICIs) in the medical fields." Highlights in Science, Engineering and Technology 36 (March 21, 2023): 321–30. http://dx.doi.org/10.54097/hset.v36i.5698.

Full text

Abstract:

ICIs are a kind of immunotherapy that works by preventing immune checkpoints from functioning normally, which are essential immune system components. ICIs are currently the most used immunotherapy regimen. Based on the patient's health, the cancer type, the length of the illness, and the dose of inhibitors the patient can tolerate, the therapy can cause side effects of indeterminate duration and varying degrees. However, the therapy remains beneficial for patients. Therefore, the effects of immunotherapy on the human body are still an issue that needs to be explored. An overview of ICIs in immunotherapy will be given in this paper, including the following concepts: (i) General information on treatments with immune checkpoint inhibitors (ii)The immunotherapy’s mechanism and application (iii) Problems and complications with ICI therapies (iv) Ways that the immunotherapy can be improved and the future direction of ICI.

APA, Harvard, Vancouver, ISO, and other styles

9

Gillespy, Kristen, Margie D. Dixon, and Rebecca D. Pentz. "Communication about immunotherapy: Barriers and information to discuss." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 6543. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.6543.

Full text

Abstract:

6543 Background: Since immunotherapy is a promising new therapeutic approach to cancer treatment, improving physician/patient communication about this approach is important. No communication guidelines exist. To begin to fill this gap, we identified provider and patient preferences for information, and identified barriers to communication about immunotherapy. Methods: We qualitatively interviewed 15 oncology professionals who offer immunotherapy treatment about the information they deemed important to communicate to patients and the communication barriers. After a discussion about immunotherapy options with a provider, we interviewed 18 oncology patients about the information that was most useful to them and their impressions of immunotherapy. We captured impressions on two 1-5 scales with 5 being ‘very positive impression’ and ‘very likely to be cured’ and by picking words from a list of positive and negative terms like ‘effective’ and ‘risky.’ All open-ended questions were qualitatively coded. We reached saturation of themes with 18 patients. Results: Patients identified 4 useful topics to discuss: treatment options, benefits, treatment logistics, and side effects. Providers identified 3 topics important topics to convey: side effects, realistic view of benefit and treatment logistics. The most frequently provider-identified barrier to communication was patients’ baseline misconceptions about immunotherapy’s effectiveness. Supporting this, patients’ impressions were very positive (average of 4 on impressions scale and 3.9 on potential to be cured scale.) The most frequently chosen word patients chose to describe immunotherapy treatment was ‘hopeful’ (10/18 55%). Conclusions: There is largely agreement on the important topics to discuss about immunotherapy, though half of the patients thought a discussion of treatment options would be useful and only one physicians mentioned options. Of note, communication is hampered by patients’ preconceptions about immunotherapy’s effectiveness. Communication guidelines should identify techniques to effectively overcome this barrier.

APA, Harvard, Vancouver, ISO, and other styles

10

&NA;. "Immunotherapy." Reactions Weekly &NA;, no. 548 (April 1995): 8. http://dx.doi.org/10.2165/00128415-199505480-00029.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

&NA;. "Immunotherapy." Reactions Weekly &NA;, no. 550 (May 1995): 10. http://dx.doi.org/10.2165/00128415-199505500-00031.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

&NA;. "Immunotherapy." Reactions Weekly &NA;, no. 583 (January 1996): 9. http://dx.doi.org/10.2165/00128415-199605830-00024.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Volkov, N. M. "IMMUNOTHERAPY." Practical oncology 19, no. 3 (September 30, 2018): 226–35. http://dx.doi.org/10.31917/1903226.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

&NA;. "Immunotherapy." Reactions Weekly &NA;, no. 450 (May 1993): 11. http://dx.doi.org/10.2165/00128415-199304500-00051.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

&NA;. "Immunotherapy." Reactions Weekly &NA;, no. 663 (August 1997): 8. http://dx.doi.org/10.2165/00128415-199706630-00015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

&NA;. "Immunotherapy." Reactions Weekly &NA;, no. 667 (September 1997): 10. http://dx.doi.org/10.2165/00128415-199706670-00030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Reisman, Robert E., and Michael J. Tronolone. "IMMUNOTHERAPY." Radiologic Clinics of North America 20, no. 3 (August 2000): 469–78. http://dx.doi.org/10.1016/s0033-8389(22)00102-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Wilkinson, Anna N. "Immunotherapy." Canadian Family Physician 67, no. 7 (July 2021): 512–15. http://dx.doi.org/10.46747/cfp.6707512.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

&NA;. "Immunotherapy." Reactions Weekly &NA;, no. 375 (November 1991): 8. http://dx.doi.org/10.2165/00128415-199103750-00043.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

&NA;. "Immunotherapy." Reactions Weekly &NA;, no. 398 (April 1992): 9. http://dx.doi.org/10.2165/00128415-199203980-00029.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

&NA;. "Immunotherapy." Reactions Weekly &NA;, no. 406 (June 1992): 9. http://dx.doi.org/10.2165/00128415-199204060-00034.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

&NA;. "Immunotherapy." Reactions Weekly &NA;, no. 415 (August 1992): 9. http://dx.doi.org/10.2165/00128415-199204150-00044.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

&NA;. "Immunotherapy." Reactions Weekly &NA;, no. 423 (October 1992): 9. http://dx.doi.org/10.2165/00128415-199204230-00036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Einsele, Hermann. "IMMUNOTHERAPY." HemaSphere 6 (April 2022): 5. http://dx.doi.org/10.1097/01.hs9.0000829536.89700.39.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

&NA;. "Immunotherapy." Reactions Weekly &NA;, no. 337 (February 1991): 6. http://dx.doi.org/10.2165/00128415-199103370-00034.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

&NA;. "Immunotherapy." Reactions Weekly &NA;, no. 353 (June 1991): 6. http://dx.doi.org/10.2165/00128415-199103530-00032.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

&NA;. "Immunotherapy." Reactions Weekly &NA;, no. 354 (June 1991): 9. http://dx.doi.org/10.2165/00128415-199103540-00037.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

&NA;. "Immunotherapy." Reactions Weekly &NA;, no. 360 (July 1991): 8. http://dx.doi.org/10.2165/00128415-199103600-00038.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

&NA;. "Immunotherapy." Reactions Weekly &NA;, no. 361 (July 1991): 7. http://dx.doi.org/10.2165/00128415-199103610-00033.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Cleton-Jansen, Anne-Marie, Emilie P. Buddingh, and Arjan C. Lankester. "Immunotherapy." OncoImmunology 1, no. 2 (March 2012): 255–57. http://dx.doi.org/10.4161/onci.1.2.18345.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

&NA;. "Immunotherapy." Reactions Weekly &NA;, no. 479 (November 1993): 9. http://dx.doi.org/10.2165/00128415-199304790-00030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

&NA;. "Immunotherapy." Reactions Weekly &NA;, no. 483 (January 1994): 8. http://dx.doi.org/10.2165/00128415-199404830-00036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

&NA;. "Immunotherapy." Reactions Weekly &NA;, no. 484 (January 1994): 7. http://dx.doi.org/10.2165/00128415-199404840-00027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Malling, Hans-Jergen. "IMMUNOTHERAPY." Allergy 43 (May 1988): 9–33. http://dx.doi.org/10.1111/j.1398-9995.1988.tb04767.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Davarpanah, Nicole N., Akira Yuno, Jane B. Trepel, and Andrea B. Apolo. "Immunotherapy." Current Opinion in Oncology 29, no. 3 (May 2017): 184–95. http://dx.doi.org/10.1097/cco.0000000000000366.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Wang, Daniel, Jill Gilbert, and Young J. Kim. "Immunotherapy." Otolaryngologic Clinics of North America 50, no. 4 (August 2017): 867–74. http://dx.doi.org/10.1016/j.otc.2017.04.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Damask, Cecelia. "Immunotherapy." Otolaryngologic Clinics of North America 50, no. 6 (December 2017): 1153–65. http://dx.doi.org/10.1016/j.otc.2017.08.012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Vansteenkiste, J. "Immunotherapy." Lung Cancer 77 (June 2012): S17—S18. http://dx.doi.org/10.1016/j.lungcan.2012.05.030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Fujita, M., G. Kohanbash, H. A. McDonald, L. Delamarre, S. A. Decker, J. R. Ohlfest, H. Okada, et al. "Immunotherapy." Neuro-Oncology 12, Supplement 4 (October 21, 2010): iv32—iv36. http://dx.doi.org/10.1093/neuonc/noq116.s5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Hickey, M. J., C. K. Malone, K. L. Erickson, L. E. Gerschenson, A. H. Lin, A. Inagaki, K. Hiraoka, et al. "IMMUNOTHERAPY." Neuro-Oncology 13, suppl 3 (October 21, 2011): iii34—iii40. http://dx.doi.org/10.1093/neuonc/nor151.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Weinberg, J. "Immunotherapy." Current Opinion in Infectious Diseases 2, no. 4 (August 1989): 582–86. http://dx.doi.org/10.1097/00001432-198908000-00015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Reisman, Robert E., and Michael J. Tronolone. "IMMUNOTHERAPY." Immunology and Allergy Clinics of North America 20, no. 3 (August 2000): 469–78. http://dx.doi.org/10.1016/s0889-8561(05)70161-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Allison, James P. "Immunotherapy." Current Opinion in Immunology 14, no. 5 (October 2002): 631–32. http://dx.doi.org/10.1016/s0952-7915(02)00392-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Suh, Robert D. "Immunotherapy." Journal of Vascular and Interventional Radiology 12, no. 1 (January 2001): P217—P221. http://dx.doi.org/10.1016/s1051-0443(01)70121-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Morris, David L., Vijay K. Sabnis, George F. Kroker, and Mary S. Morris. "IMMUNOTHERAPY." Annals of Allergy, Asthma & Immunology 85, no. 6 (December 2000): 514. http://dx.doi.org/10.1016/s1081-1206(10)62584-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Kullberg, Bart-Jan, Frank van de Veerdonk, and Mihai G. Netea. "Immunotherapy." Current Opinion in Infectious Diseases 27, no. 6 (December 2014): 511–16. http://dx.doi.org/10.1097/qco.0000000000000105.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Osguthorpe, John David. "Immunotherapy." Current Opinion in Otolaryngology & Head and Neck Surgery 18, no. 3 (June 2010): 206–12. http://dx.doi.org/10.1097/moo.0b013e3283385881.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Afifi, Salma, Angela Michael, and Alexander Lesokhin. "Immunotherapy." Annals of Pharmacotherapy 50, no. 7 (April 15, 2016): 555–68. http://dx.doi.org/10.1177/1060028016642786.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Marcus, Sonya. "Immunotherapy." JAMA Otolaryngology–Head & Neck Surgery 146, no. 10 (October 1, 2020): 988. http://dx.doi.org/10.1001/jamaoto.2020.1798.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

James, D. Geraint. "Immunotherapy." International Journal of Clinical Practice 43, no. 12 (December 1989): 433–37. http://dx.doi.org/10.1111/j.1742-1241.1989.tb08797.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!